{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-010161","form_type":"8-K","ticker":null,"cik":"0001651407","company_name":"Checkpoint Therapeutics, Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.983307+00:00","generated_at":"2026-06-06T09:57:07.296717+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Checkpoint Therapeutics fails Nasdaq board independence rule after director resignation","bullets":["Scott Boilen resigned from Board effective Jan 31, 2024; company no longer has majority independent directors as required by Nasdaq Rule 5605(b)(1).","Nasdaq confirmed non-compliance via letter on Feb 2, 2024; no immediate impact on listing or trading of CKPT common stock.","Company has cure period until earlier of next annual shareholders' meeting or Jan 31, 2025; if annual meeting before July 29, 2024, compliance due July 29, 2024.","Board intends to regain compliance with Board Independence Rule before cure period expires."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-010161","json":"https://secwatch.observer/filing/0001104659-24-010161.json","markdown":"https://secwatch.observer/filing/0001104659-24-010161.md","text":"https://secwatch.observer/filing/0001104659-24-010161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/0001104659-24-010161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/tm245111d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:57:07.296717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16b6729794fd83cf54dfa8e4ae94e4e0ae1134e2","claim":"Checkpoint Therapeutics, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(a)(2)).","evidence_excerpt":"February 2, 2024, the Company received a letter from Nasdaq confirming that the Company was no longer in compliance with the Board Independence Rule. The Company’s non-compliance with the Board Independence Rule does not have an immediate effect on the listing or trading of the Company’s common stock, which continues to be listed and traded on the Nasdaq Capital Market under the symbol “CKPT.” In accordance with Rule 5605(b)(1)(A) of the Nasdaq listing standards, the Company has until the earlier of its next annual shareholders’ meeting or January 31, 2025, to regain compliance; provided, howe","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/0001104659-24-010161-index.htm","confidence":0.97,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"board independence"},{"label":"Rules","value":"5605(b)(1), 5605(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}